News | March 19, 2008

Free Laboratory Test Selection Support Link Available for PDA, via Web

March 20, 2008 - ARUP Laboratories and the University of Utah's Department of Pathology have released ARUP Consult version 2.3, a free laboratory test selection support tool for PDA devices that includes more than 1,500 lab tests categorized into disease-related topics, including clinical background information, test ordering suggestions and concise diagnostic advice.

ARUP Consult is a no-cost Web site that allows physicians to search by disease or condition and find current lab test suggestions, interpretations, algorithms, concise diagnostic advice, and recommendations congruent with national guidelines and supportive links to PubMed and the NGC. It is designed for use at the point of care via the Web or using PDA platforms.

ARUO Laboratories said nearly $5 billion was lost in 2007 because of unnecessary lab testing.

The site offers direct links to national guidelines and relevant references, has more than 40 algorithms to help support clinical decision-making, and has new and updated content released six times a year. The software is co-authored and maintained by ARUP Laboratories' expert panel of University of Utah faculty.

For more information: www.arupconsult.com


Additional Content

News | Pharmaceuticals

July 16, 2026 — Merck has received U.S. Food and Drug Administration (FDA) approval for Lipfendra (enlicitide) tablets ...

Home July 16, 2026
Home
News | Pharmaceuticals

Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 ...

Home January 28, 2026
Home
News | Pharmaceuticals

Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...

Home November 19, 2025
Home
News | Pharmaceuticals

Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...

Home September 25, 2025
Home
News | Pharmaceuticals

Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...

Home September 23, 2025
Home
Subscribe Now